SOPHiA GENETICS (NASDAQ:SOPH) Sees Large Volume Increase – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) shares saw unusually-high trading volume on Monday . Approximately 134,486 shares traded hands during trading, a decline of 43% from the previous session’s volume of 234,441 shares.The stock last traded at $8.65 and had previously closed at $8.65.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SOPH. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright boosted their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Stock Up 2.4%

The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a market capitalization of $725.65 million, a price-to-earnings ratio of -7.52 and a beta of 0.96. The firm’s fifty day moving average is $6.33 and its 200-day moving average is $5.37.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Insider Transactions at SOPHiA GENETICS

In related news, insider Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the transaction, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jurgi Camblong sold 50,069 shares of the business’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $5.80, for a total value of $290,400.20. Following the completion of the sale, the chief executive officer directly owned 3,601,493 shares of the company’s stock, valued at approximately $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 313,592 shares of company stock valued at $1,927,565. Insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC grew its position in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after acquiring an additional 4,155 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after purchasing an additional 6,205 shares during the last quarter. Principal Financial Group Inc. boosted its stake in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the period. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter valued at about $50,000. Finally, Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth about $49,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.